I thought the earnings were pretty decent. Obviously the market disagrees but I would love to hear your opinions of the earnings and today’s consequent drop in price.
02:35 AM EST, 02/10/2026 (MT Newswires) -- GSK (GSK.L) said China's Center for Drug Evaluation accepted for review its application for Arexvy as a vaccine in adults against respiratory syncytial virus-caused lower respiratory tract disease. According to a Tuesday filing, the British drugmaker is seeking approval in China for the use of the vaccine in adults aged at least 60 years. It supported the application with positive data from a phase 3 trial, and a regulatory decision is expected in 2027.
I thought the results today were decent, nice dividend growth for the upcoming and next year as well as the share buybacks. Market seems happy with the results what do you all think?
News on a new purchase for $GSK to strengthen its position in respiratory, immunology & inflammation offerings.
https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-buy-rapt-therapeutics-22-billion-2026-01-20/
GSK Q3 2025 Earnings in 5 Days: Execution vs. FX & IRA headwinds
When: Wed 29 Oct 2025, 07:00 GMT; management presentation follows (webcast link on GSK IR).
Street sees steady quarter with specialty meds leading; focus on whether FY25 stays “top-end” of guidance as FX and US policy headwinds bite.
4 Key Takeaways
• Consensus (Q3’25E): Turnover £8.24bn, Core EPS ~47.1p, Op. margin ~32.4%; WANS ~4,036m (buybacks reduce share count).
• FY25 Guidance (CER): Sales +3–5%, Core OP +6–8%, Core EPS +6–8%, management guiding toward the top end.
• Returns: FY25 dividend run-rate ~64p indicated earlier; £2bn buyback programme underway (three tranches completed/underway YTD).
• Watchpoints (Q3): FX −1% to −2% drag on sales; US IRA Part D redesign ~£400–500m FY headwind; step-up in SG&A to support launches; vaccine mix (Shingrix/Arexvy seasonality) and oncology momentum (Jemperli/Ojjaara).
⭐ Star Rating
• Dividend Strength: ⭐⭐⭐⭐☆
• Financial Health: ⭐⭐⭐⭐☆
• Growth/Pipeline: ⭐⭐⭐☆☆
• Valuation: ⭐⭐⭐☆☆
• Management/Execution: ⭐⭐⭐⭐☆
Overall: ⭐⭐⭐⭐☆ (4/5) Solid execution and shareholder returns; mind FX/IRA and vaccine mix into Q4.
If specialty meds + oncology keep comping strong and FX/IRA headwinds are contained, GSK can hold the top-end FY25 guide. I’ll be watching EPS leverage vs. SG&A step-up and any colour on Arexvy/Shingrix trajectory into Q4.
ccc1990
prije 8 mjeseci
Lovely stuff
ContrarianCNT
prije 8 mjeseci
What's happening guys?
Unable to check what's going on. Biggest daily pop I can remember on GSK.
Na ovoj se stranici možda nalazi sadržaj koji je izradila zajednica za koji platforma Trading 212 nije odgovorna. Uvijek sami provjerite sve informacije. Trading 212 pruža samo uslugu izvršenja i ne nudi investicijske savjete ili upravljanje portfeljem.
Izgradnja bogatstva je navika. Automatiziraj je pomoću pie.
Uloži u gotove pies ili stvori vlastite odabirom među tisućama dionica i ETF-ova
Saznaj više
Saznaj više
Pogledaj video
Kupi čak i najskuplje dionice kao što su Google, Amazon i Apple
Pogledaj video
Euronext Pariz
NYSE, NASDAQ
Xetra, Gettex
Euronext Amsterdam
Bolsa de Madrid
Wiener Börse
Londonska burza
Euronext Lisabon
Euronext Pariz
NYSE, NASDAQ
Xetra, Gettex
Euronext Amsterdam
Bolsa de Madrid
Wiener Börse
Londonska burza
Euronext Lisabon
Prikaži sve instrumente trgovanja
Podrška 24/7
Prosječno vrijeme odgovora iznosi 29 sekundi
Počni graditi svoje bogatstvo sada
Pridruži se zajednici od 5 milijuna korisnika
Preuzmi aplikaciju
Otvori račun
Preuzmi mobilnu aplikaciju
Svi prikazani statistički podaci su globalni. Broj klijenata predstavlja financirane račune.
Izvrsno
Ocjena 4,6 / 5 na osnovi 93.567 recenzije/a s platforme
Trustpilot
Ocjena 4,6 / 5 na osnovi 93.567 recenzije/a s platforme
Trustpilot
Pozvan
Great
Immediate updates, easy to use and manage.
Pozvan
Very easy to use
Very easy to use. Intuitive app and makes it straight forward to sit back and let your investment's do its work
Pozvan
Ease of use
Easy to set up an account
Easy to transfer funds
Great interest rate
Great all round experience
Pozvan
Easy to set up my account
Easy to set up my account easy to access balance and a very good rate in interest.
Pozvan
easy to use platform
easy to use platform, love the ability to transfer cash isa funds into stocks and shares isa
Pozvan
Simple and Informative platform
I wanted a platform which was offering great rates for my ISA, but discovered not only did this platform do that. It also gave me an insight into trading and world markets. It's quite simply brilliant.
Pozvan
Great app that provides all my account…
Great app that provides all my account info at my fingertips
Pozvan
Easy to use.
Easy to use.
Can view everything simply.
Just what I need.
Pozvan
Good interest rate and can take the…
Good interest rate and can take the money out whenever I want.
Pozvan
So easy
So easy! Makes investing a pleasure
Pozvan
I’m novice and useless with technology…
I’m novice and useless with technology but I found this an easy site to navigate and to deal with.
Pozvan
Nice app
Great app, very intuitive and simple to use. Gold standard.
Pozvan
Very easy to use
Very easy to use. Very clear. And a joy to watch my savings rise
Pozvan
Easy to use
Functional and easy to use and track my cash & stocks & shares isas
Pozvan
Easy access to my account and how Easy…
Easy access to my account and how Easy it is to navigate the212 application.
Pozvan
Simple and easy to use app
Simple and easy to use app. Ease of setting up recurring payments. Great for a beginner that has no prior knowledge or experience of investing.
Pozvan
Easy and simple app
Easy and simple app, tells you daily your interest which I like and I get emails. The updating is really good.
Pozvan
Very easy and highly recommend
Very easy and highly recommend. Straight forward to use and cost instructions on the fees and charges.
Pozvan
Great way for your money to build
Just very pleased with the level of savings rate and steady build up.
Pozvan
Cool app
User friendly mobile app that makes investing easy and funny. Fast navigation throughout the app. In a few clicks can see basically every information one might require.
Prikazuju se neke od pozitivnih recenzija naših klijenata
Naše nagrade
Česta pitanja
Koja je cijena dionice GSK (GSK)?
Trenutna cijena GSK (GSK) je 1.901,8 GBX.
Koji je 52-tjedni maksimum za GSK?
52-tjedni maksimum za GSK je 2.281,7 GBX.
Koji je 52-tjedni minimum za GSK?
52-tjedni minimum za GSK je 1.318,7 GBX.
Kakva je tjedna učinkovitost GSK?
U proteklom tjednu cijena GSK promijenila se za −0,84 %.
Kakva je mjesečna učinkovitost GSK?
Tijekom proteklog mjeseca, cijena GSK promijenila se za 0,04 %.
Kakva je 3-mjesečna performansa GSK?
U posljednja tri mjeseca cijena GSK promijenila se za −10,38 %.
Kakva je 6-mjesečna performansa GSK?
U posljednjih šest mjeseci cijena GSK promijenila se za 3,75 %.
Kakva je godišnja učinkovitost GSK?
Tijekom protekle godine cijena GSK promijenila se za 28,07 %.